167 related articles for article (PubMed ID: 1354963)
1. Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance.
Cuvier C; Roblot-Treupel L; Millot JM; Lizard G; Chevillard S; Manfait M; Couvreur P; Poupon MF
Biochem Pharmacol; 1992 Aug; 44(3):509-17. PubMed ID: 1354963
[TBL] [Abstract][Full Text] [Related]
2. [Vectorisation of doxorubicin in nanospheres and reversion of pleiotropic resistance of tumor cells].
Treupel L; Poupon MF; Couvreur P; Puisieux F
C R Acad Sci III; 1991; 313(3):171-4. PubMed ID: 1913255
[TBL] [Abstract][Full Text] [Related]
3. In vitro effects of pentoxifylline and doxorubicin on cell survival and DNA damage in sensitive and MDR-P388 leukemia cells.
Viladkar A; Chitnis M
Cancer Biother; 1994; 9(2):143-51. PubMed ID: 7812363
[TBL] [Abstract][Full Text] [Related]
4. Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin-14-O-hemiadipate.
Leontieva OV; Preobrazhenskaya MN; Bernacki RJ
Invest New Drugs; 2002 Feb; 20(1):35-48. PubMed ID: 12003193
[TBL] [Abstract][Full Text] [Related]
5. Uptake of doxorubicin from loaded nanoparticles in multidrug-resistant leukemic murine cells.
Colin de Verdière A; Dubernet C; Nemati F; Poupon MF; Puisieux F; Couvreur P
Cancer Chemother Pharmacol; 1994; 33(6):504-8. PubMed ID: 8137462
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of pirarubicin cytotoxicity by dipyridamole in doxorubicin-resistant mouse P388 leukemia cells.
Furusawa S; Fujimura T; Kawauchi H; Sasaki K; Takayanagi Y
Res Commun Chem Pathol Pharmacol; 1991 Mar; 71(3):321-36. PubMed ID: 2047575
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantrone.
Kamath N; Grabowski D; Ford J; Kerrigan D; Pommier Y; Ganapathi R
Biochem Pharmacol; 1992 Sep; 44(5):937-45. PubMed ID: 1356339
[TBL] [Abstract][Full Text] [Related]
8. Reversal of multidrug resistance by an immunosuppressive agent FK-506.
Naito M; Oh-hara T; Yamazaki A; Danki T; Tsuruo T
Cancer Chemother Pharmacol; 1992; 29(3):195-200. PubMed ID: 1370765
[TBL] [Abstract][Full Text] [Related]
9. Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes.
Thierry AR; Vigé D; Coughlin SS; Belli JA; Dritschilo A; Rahman A
FASEB J; 1993 Apr; 7(6):572-9. PubMed ID: 8097173
[TBL] [Abstract][Full Text] [Related]
10. Ability of doxorubicin-loaded nanoparticles to overcome multidrug resistance of tumor cells after their capture by macrophages.
Soma CE; Dubernet C; Barratt G; Nemati F; Appel M; Benita S; Couvreur P
Pharm Res; 1999 Nov; 16(11):1710-6. PubMed ID: 10571276
[TBL] [Abstract][Full Text] [Related]
11. Quantification of the expression of multidrug resistance-related genes in human tumour cell lines grown with free doxorubicin or doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres.
Laurand A; Laroche-Clary A; Larrue A; Huet S; Soma E; Bonnet J; Robert J
Anticancer Res; 2004; 24(6):3781-8. PubMed ID: 15736412
[TBL] [Abstract][Full Text] [Related]
12. Sequestration of doxorubicin in vesicles in a multidrug-resistant cell line (LZ-100).
Sognier MA; Zhang Y; Eberle RL; Sweet KM; Altenberg GA; Belli JA
Biochem Pharmacol; 1994 Jul; 48(2):391-401. PubMed ID: 7914406
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of adriamycin-induced cytotoxicity by increasing retention and inhibition of DNA repair in DOX-resistant P388 cell lines with new calcium channel blocker, DMDP.
Bankusli I; Yin MB; Mazzoni A; Abdellah AJ; Rustum YM
Anticancer Res; 1989; 9(3):567-74. PubMed ID: 2764503
[TBL] [Abstract][Full Text] [Related]
14. Identification of two distinct intracellular sites that contribute to the modulation of multidrug resistance in P388/ADR cells expressing P-glycoprotein.
Mayer LD; Lim KT; Hartley D
J Exp Ther Oncol; 2002; 2(2):107-20. PubMed ID: 12415627
[TBL] [Abstract][Full Text] [Related]
15. Effects of a new triazinoaminopiperidine derivative on adriamycin accumulation and retention in cells displaying P-glycoprotein-mediated multidrug resistance.
Léonce S; Pierré A; Anstett M; Pérez V; Genton A; Bizzari JP; Atassi G
Biochem Pharmacol; 1992 Nov; 44(9):1707-15. PubMed ID: 1360210
[TBL] [Abstract][Full Text] [Related]
16. Effect of S9788, cyclosporin A and verapamil on intracellular distribution of THP-doxorubicin in multidrug-resistant K562 tumor cells, as studied by laser confocal microspectrofluorometry.
Sebille S; Morjani H; Poullain MG; Manfait M
Anticancer Res; 1994; 14(6A):2389-93. PubMed ID: 7825978
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein expression and modulation of cell-membrane morphology in adriamycin-resistant P388 leukemia cells.
Radel S; Fredericks W; Mayhew E; Baker R
Cancer Chemother Pharmacol; 1990; 25(4):241-6. PubMed ID: 1967228
[TBL] [Abstract][Full Text] [Related]
18. Reversal of resistance to doxorubicin with cepharanthine in murine P388 leukemia cells.
Fujimura T; Shibata H; Maekawa I; Furusawa S; Kawauchi H; Sasaki K; Takayanagi Y
Jpn J Pharmacol; 1990 Dec; 54(4):464-7. PubMed ID: 2087009
[TBL] [Abstract][Full Text] [Related]
19. Modulation of thiol pools by vitamin K3 and its effect on survival of sensitive and resistant murine tumor cells.
Parekh H; Chavan S; Chitnis M
Anticancer Drugs; 1991 Apr; 2(2):159-68. PubMed ID: 1683589
[TBL] [Abstract][Full Text] [Related]
20. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
Goren D; Horowitz AT; Tzemach D; Tarshish M; Zalipsky S; Gabizon A
Clin Cancer Res; 2000 May; 6(5):1949-57. PubMed ID: 10815920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
